Comments Regarding Identification, Assessment, and Control of Nitrosamine Drug Substance-Related Impurities in Human Drug Products Share page: Docket Number: FDA-2023-N-1585-0001 Download Document Issues: OTC Medicines Other Issues Quality Related Posts Comments Comments Regarding FDA Annual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products May 13, 2024 Press Releases and Statements CHPA Applauds Vermont for Passing Sun Safety Bill Empowering Students to Better Protect their Skin May 8, 2024 Press Releases and Statements Tennessee Expands Access to OTC Cold & Allergy Medications Containing PSE May 7, 2024